VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

200952 citationsJournal Article

Authors

Good health and well-being

Published in: Lung Cancer

Volume 69, Issue 3, pp. 337-340

Field-Weighted Citation Impact: 4.30